Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.

MLA

Arévalo-Herrera, Myriam, et al. “Immunogenicity of Full-Length P. Vivax RPvs48/45 Protein Formulations in BALB/c Mice.” Vaccine, vol. 40, no. 1, Jan. 2022, pp. 133–40. EBSCOhost, https://doi.org/10.1016/j.vaccine.2021.11.036.

APA

Arévalo-Herrera, M., Miura, K., Solano, E., Sebastián Ramírez, J., Long, C. A., Corradin, G., & Herrera, S. (2022). Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice. Vaccine, 40(1), 133–140. https://doi.org/10.1016/j.vaccine.2021.11.036

Chicago

Arévalo-Herrera, Myriam, Kazutoyo Miura, Eduardo Solano, Juan Sebastián Ramírez, Carole A Long, Giampietro Corradin, and Sócrates Herrera. 2022. “Immunogenicity of Full-Length P. Vivax RPvs48/45 Protein Formulations in BALB/c Mice.” Vaccine 40 (1): 133–40. doi:10.1016/j.vaccine.2021.11.036.